Compare Quest Diagnostics Inc (DGX) vs Synopsys, Inc. (SNPS) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Quest Diagnostics Inc vs Synopsys, Inc. — how do they compare? Quest Diagnostics Inc trades at $202.3 (market cap $22.80B), while Synopsys, Inc. trades at $427 (market cap $81.55B). The key difference: Synopsys, Inc. is far larger — about 3.6× Quest Diagnostics Inc's market cap, and Quest Diagnostics Inc pays a 1.67% dividend while Synopsys, Inc. pays none. Which is the better fit depends on your goals.
| DGX | SNPS | |
|---|---|---|
Market Cap | $22.80B | $81.55B |
Sector | Health | Technology |
52-Week High | $216.02 | $645.59 |
52-Week Low | $166.42 | $380.47 |
Enterprise Value | $28.82B | $89.91B |
Dividend Yield | 1.67% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Quest Diagnostics (DGX) trades at $207.35, showing minimal daily movement with a slight decline of 0.04%. The stock maintains a bullish technical stance with recent earnings beats and analyst consensus pointing to upside potential. Recent developments include New York State approval for Haystack MRD testing and strong momentum across diagnostic channels. Revenue growth accelerated to $11.04 billion in 2025 with consistent profitability margins around 9%.
DGX presents a balanced investment case with 38% analyst buy ratings and a $227.75 price target suggesting 10% upside. The company demonstrates steady revenue growth and operational efficiency, though elevated debt levels and policy risks require monitoring. Second quarter earnings on July 23, 2026, will be crucial for validating current momentum and growth trajectory.
Synopsys (SNPS) trades at $433.82, down 2.6% today, with a bearish technical signal from moving averages but oversold short-term RSI at 29.08. The company reported strong earnings beats in recent quarters, with Q1 2026 EPS of $3.35 surpassing the $3.15 estimate. Revenue grew to $7.05B in 2025, though net income margin compressed to 8.91%. Valuation multiples remain elevated with a P/E of 99.27 and P/S of 9.16. Recent news highlights Synopsys' strategic pivot toward AI-driven design tools and multiphysics solutions.
Outlook: Analyst consensus is bullish with an average price target of $558.33, implying 29% upside, supported by 24 buy ratings. Risks include integration challenges from the Ansys acquisition, competitive pressures in EDA software, and volatility in semiconductor capex. The stock's high valuation requires sustained execution on AI-related growth to justify further gains.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Quest Diagnostics Inc
Quest Diagnostics is a leading independent provider of diagnostic testing, information, and services in the U.S. The company generates over 95% of its revenue through clinical testing, anatomic pathology, esoteric testing, and substance abuse testing with specimens collected at its national network of roughly 2,300 patient service centers, as well as multiple doctors offices and hospitals. The firm also runs a much smaller diagnostic solutions segment that provides clinical trials testing, risk assessment services, and information technology solutions.
Read more on DGX →About Synopsys, Inc.
Synopsys is a provider of electronic design automation software, intellectual property, and software integrity products. EDA software automates the chip design process, enhancing design accuracy, productivity, and complexity in a full-flow end-to-end solution. The firm's growing SI business allows customers to continuously manage and test the code base for security and quality. Synopsys' comprehensive portfolio is benefiting from a mutual convergence of semiconductor companies moving up-stack toward systems-like companies, and systems companies moving down-stack toward in-house chip design. The resulting expansion in EDA customers alongside secular digitalization of various end markets benefits EDA vendors like Synopsys.
Read more on SNPS →
